Targeted Molecular Therapy for Renal Cell Carcinoma: Impact on Existing Treatment Paradigms

This activity is an archive of the live session held at the 2009 Fall Managed Care Forum. If you participated in the live activity, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2010 to December 31, 2011.
These presentations require Internet Explorer 5.0 or later, Netscape Navigator 7.0 or later, or Internet Explorer 5.2.2 for Mac.  To Download the latest version of Internet Explorer from the Microsoft web site, click here.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Novartis Pharmaceuticals
PLEASE CLICK HERE TO VIEW THE ARTICLE

 PLEASE CLICK HERE FOR POST TEST AND EVALUATION

Instructions for CME/CEU: Read the article, answer the post test, complete the evaluation form, and hit submit. A score of 70% must be achieved on the post test to receive continuing education credits. You will have the option on the post test/evaluation page to submit your forms electronically or you can fax them to Katie Eads at 804-747-5316.

Description
The treatment of renal cancers is evolving very quickly. As knowledge of the molecular pathways key to the growth of cancer cells has become available, targeted therapies that disrupt these pathways have been developed. Although many questions remain about the optimal use of these agents, the median survival time for patients has been significantly increased.


Upon Completion of this activity, participants will be able to:

  • Describe the benefits and limitations of current treatment approaches for patients with advanced Renal Cell Carcinoma (RCC)

  • Identify novel immunotherapies undergoing late-stage development in advanced RCC

  • Review the recently updated NCCN Kidney Cancer Guidelines

  • Describe the rationale of current clinical trials and how emerging clinical data may impact the treatment of patients with advanced RCC

  • Discuss combination treatments under investigation in patients with RCC
     

Faculty: Wolfram Samlowski, MD
Professor & Chief
Section of Melanoma, Renal Cancer & Immunotherapy
Nevada Cancer Institute

Disclosure:

 Dr. Samlowski receives consulting fees from Abraxis, Genentech and Pfizer and serves on speaker’s bureaus for Novartis and Pfizer.
  Planning Committee:
 Bill Williams, MD has no real or perceived financial relationships to disclose.
 Katie Eads has no real or perceived financial relationships to disclose.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. NAMCP designates this activity for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses (AAMCN) has been approved as a provider of continuing education by the Virginia Nurses Association (VNA). VNA is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will be awarded 1.0 contact hours.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

   

This activity is supported by an educational grant from Novartis Pharmaceuticals

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.